T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: An infusion of cytomegalovirus-specific T lymphocytes may prevent or reduce cytomegalovirus infection during the first year after a donor stem cell transplant.

PURPOSE: This randomized phase II trial is studying T-lymphocyte infusion to see how well it works compared with standard therapy in treating patients at risk of cytomegalovirus infection after a donor stem cell transplant.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Birmingham
• Treatments: Alemtuzumab; Foscarnet; Ganciclovir; Ganciclovir triphosphate; Phosphonoacetic Acid

Criteria

DISEASE CHARACTERISTICS:

• Planning allogeneic peripheral blood stem cell transplantation (PBSCT) using a conditioning regimen containing alemtuzumab and radiotherapy

• Sibling or matched unrelated donor available

• Patients and donor matched for ≥ one of the following HLA alleles:

• HLA-A*0101

• HLA*0201

• HLA-A*1101

• HLA-A*2402

• HLA-B*0702

• HLA-B*0801

• HLA-B*3502

• No donors whose stem cells have already been collected and cryopreserved prior to transplant

• Patient and donor must be CMV seropositive

• Stem cell harvests ≥ 4.0 x 10^6 CD34 cells/kg

PATIENT CHARACTERISTICS:

• See Disease Characteristics

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior bone marrow transplantation

• No concurrent participation in another therapeutic transplantation study